3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
211
Recurrence
27
Neoplasms, Plasma Cell
15
Neoplasms
13
Immunoglobulin Light-chain Amyloidosis
13
Leukemia, Myeloid, Acute
9
Lymphoma, Non-Hodgkin
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Smoldering Multiple Myeloma
5
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
4
Hematologic Neoplasms
4
Plasmacytoma
3
Paraproteinemias
3
Myelodysplastic Syndromes
3
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Hematologic Diseases
3
Carcinoma, Non-Small-Cell Lung
3
Amyloidosis
3
Waldenstrom Macroglobulinemia
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Plasmablastic Lymphoma
2
Lymphoma, Large B-Cell, Diffuse
2
Disease
2
Corneal Diseases
2
Blood Protein Disorders
2
Interventions
Temozolomide
393
Radiotherapy
196
Bevacizumab
156
Radiation
77
Magnetic Resonance Spectroscopy
68
Lomustine
47
Surgical Procedures, Operative
42
Carmustine
41
pembrolizumab
39
Irinotecan
38
Nivolumab
32
Specimen Handling
27
Carboplatin
27
Radiosurgery
24
Erlotinib Hydrochloride
24
Chemotherapy, Adjuvant
23
Radiotherapy, Intensity-Modulated
22
Drug Therapy
21
Cyclophosphamide
20
Aminolevulinic Acid
20
O(6)-benzylguanine
17
sargramostim
16
Radiotherapy, Conformal
15
temsirolimus
14
Granulocyte-Macrophage Colony-Stimulating Factor
14
Everolimus
14
Vorinostat
13
Sorafenib
13
poly ICLC
12
atezolizumab
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Glioblastoma
×
daratumumab
×
Clear all
NCT04922723
2026-04-28
PRIDE
West Virginia University
Phase 1/2
Active not recruiting
16 enrolled